Bimetallic Nanozyme : A Credible Tag for In Situ-Catalyzed Reporter Deposition in the Lateral Flow Immunoassay for Ultrasensitive Cancer Diagnosis
The lateral flow immunoassay (LFIA) is a sought-after point-of-care testing platform, yet the insufficient sensitivity of the LFIA limits its application in the detection of tumor biomarkers. Here, a colorimetric signal amplification method, bimetallic nanozyme-mediated in situ-catalyzed reporter deposition (BN-ISCRD), was designed for ultrasensitive cancer diagnosis. The bimetallic nanozyme used, palladiumiridium core-shell nanoparticles (Pd@Ir NPs), had ultrahigh enzyme-like activity, which was further explained by the electron transfer of Pd@Ir NPs and the change in the Gibbs free energy during catalysis through density functional theory calculations. With gastric cancer biomarkers pepsinogen I and pepsinogen II as model targets, this assay could achieve a cutoff value of 10 pg/mL, which was 200-fold lower than that without signal enhancement. The assay was applied to correctly identify 8 positive and 28 negative clinical samples. Overall, this BN-ISCRD-based LFIA showed great merits and potential in the application of ultrasensitive disease diagnosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Nano letters - 24(2024), 1 vom: 10. Jan., Seite 51-60 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meng, Xiangming [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7440-57-5 |
|---|
| Anmerkungen: |
Date Completed 11.01.2024 Date Revised 11.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.nanolett.3c03118 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363165177 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363165177 | ||
| 003 | DE-627 | ||
| 005 | 20240114233757.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.nanolett.3c03118 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1256.xml |
| 035 | |a (DE-627)NLM363165177 | ||
| 035 | |a (NLM)37823474 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meng, Xiangming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bimetallic Nanozyme |b A Credible Tag for In Situ-Catalyzed Reporter Deposition in the Lateral Flow Immunoassay for Ultrasensitive Cancer Diagnosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2024 | ||
| 500 | |a Date Revised 11.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The lateral flow immunoassay (LFIA) is a sought-after point-of-care testing platform, yet the insufficient sensitivity of the LFIA limits its application in the detection of tumor biomarkers. Here, a colorimetric signal amplification method, bimetallic nanozyme-mediated in situ-catalyzed reporter deposition (BN-ISCRD), was designed for ultrasensitive cancer diagnosis. The bimetallic nanozyme used, palladiumiridium core-shell nanoparticles (Pd@Ir NPs), had ultrahigh enzyme-like activity, which was further explained by the electron transfer of Pd@Ir NPs and the change in the Gibbs free energy during catalysis through density functional theory calculations. With gastric cancer biomarkers pepsinogen I and pepsinogen II as model targets, this assay could achieve a cutoff value of 10 pg/mL, which was 200-fold lower than that without signal enhancement. The assay was applied to correctly identify 8 positive and 28 negative clinical samples. Overall, this BN-ISCRD-based LFIA showed great merits and potential in the application of ultrasensitive disease diagnosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bimetallic nanozyme | |
| 650 | 4 | |a lateral flow immunoassay | |
| 650 | 4 | |a point-of-care testing | |
| 650 | 4 | |a signal amplification | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Gold |2 NLM | |
| 650 | 7 | |a 7440-57-5 |2 NLM | |
| 700 | 1 | |a Zuo, Wanchao |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Pengcheng |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yuhan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Gong-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shibo |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Xiaopeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Wenlu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Donghui |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Jianjun |e verfasserin |4 aut | |
| 700 | 1 | |a Ju, Yanmin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nano letters |d 2001 |g 24(2024), 1 vom: 10. Jan., Seite 51-60 |w (DE-627)NLM154096849 |x 1530-6992 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:10 |g month:01 |g pages:51-60 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.nanolett.3c03118 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 10 |c 01 |h 51-60 | ||